Rydex Biotechnology Fund Class H (RYOAX) - Health fund with $138.40 Million in assets. The fund allocates 37.71% of its portfolio to its top 10 holdings. It primarily invests in averagemarketcap cap stocks , with a focus on the cash and equivalents sector.
The largest holding in the fund is AbbVie, Inc. at 7.53% of total assets. This is followed by Amgen, Inc. (4.96%) and Gilead Sciences, Inc. (4.49%).
| Name | Weight | Owned | Change |
|---|---|---|---|
| AbbVie, Inc. | 7.53% | - | - |
| Amgen, Inc. | 4.96% | - | - |
| Gilead Sciences, Inc. | 4.49% | - | - |
| Regeneron Pharmaceuticals, Inc. | 3.65% | - | - |
| Vertex Pharmaceuticals, Inc. | 4.41% | - | - |
| Alnylam Pharmaceuticals, Inc. | 2.90% | - | - |
| Corteva, Inc. | 2.81% | - | - |
| Biogen, Inc. | 2.09% | - | - |
| Moderna, Inc. | 2.65% | - | - |
| AstraZeneca plc | 2.22% | - | - |
| BeiGene Ltd. | 2.40% | - | - |
| Insmed, Inc. | 2.32% | - | - |
| BeOne Medicines Ltd. | 2.04% | - | - |
| Natera, Inc. | 2.27% | - | - |